Conivaptan

Conivaptan
N-(4-(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
CAS number 210101–16–9	ATC code not yet available
Chemical formula	C₃₂H₂₆N₄O₂
Molecular weight	498.583
Bioavailability	N/A
Metabolism	?
Elimination half-life	?
Excretion	?
Pregnancy category	?
Legal status	?
Routes of administration	Intravenous

Conivaptan (YM 087) is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). It is marketed by Yamanouchi Pharmaceutical.

Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

See also